PT - JOURNAL ARTICLE AU - JULIANO ANDREOLI MIYAKE AU - MARCEL BENADIBA AU - GEISE RIBEIRO AU - DENISE DE OLIVEIRA SILVA AU - ALISON COLQUHOUN TI - Novel Ruthenium – Gamma-linolenic Acid Complex Inhibits C6 Rat Glioma Cell Proliferation <em>In Vitro</em> and in the Orthotopic C6 Model <em>In Vivo</em> After Osmotic Pump Infusion DP - 2014 Apr 01 TA - Anticancer Research PG - 1901--1911 VI - 34 IP - 4 4099 - http://ar.iiarjournals.org/content/34/4/1901.short 4100 - http://ar.iiarjournals.org/content/34/4/1901.full SO - Anticancer Res2014 Apr 01; 34 AB - Aim: Gliomas are primary brain tumours. Gamma-linolenic acid (GLA) exerts anti-proliferative effects. Several ruthenium-containing complexes have antiproliferative effects and can be used as adjuvant therapies in cisplatin-resistant cancer. The present study reports on the anti-proliferative properties and effects on tumour morphology of a novel diruthenium-GLA complex (Ru2GLA) and its comparison with GLA in the C6 rat glioma model both in vitro and in vivo. Materials and Methods: In vitro and in vivo experiments were performed on C6 glioma rat cells, and in an orthotopic model. Results: Ru2GLA (100 μM) appears to be an inhibitor of C6 rat glioma cell proliferation. The nuclear area of Ru2GLA-treated cells was 2.18-times larger than that of control cells, suggesting DNA replication occurred but mitosis was blocked in the G2-M phase. Ru2GLA (2 mM) inhibited C6 cell proliferation in vivo and the changes in tumor morphology confirm both cellular uptake and collagen fibre-binding in the extracellular matrix. Conclusion: Ru2GLA appears to be a low-toxicity drug and a potential candidate for anti-proliferative therapy of glioma.